Produktname:5-Bromo-2-chloro-3-nitropyridine
IUPAC Name:5-bromo-2-chloro-3-nitropyridine
- CAS：67443-38-3
- Molekulare Formel：C5H2BrClN2O2
- Reinheit：98%
- Katalognummer：CM102635
- Molekulargewicht：237.44
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:67443-38-3
- Molekulare Formel:C5H2BrClN2O2
- Schmelzpunkt:-
- SMILES-Code:O=[N+](C1=CC(Br)=CN=C1Cl)[O-]
- Dichte:
- Katalognummer:CM102635
- Molekulargewicht:237.44
- Siedepunkt:285.4°C at 760 mmHg
- Mdl-Nr.:MFCD00222270
- Lagerung:Keep in dark place, inert atmosphere, store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- XRD-0394
- XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.
Suche 
+86 21 5895 0110 
